FDA issues emergency use authorization for single dose Janssen COVID-19 Vaccine

Approval was based on analysis of 39,321 subjects from an ongoing global placebo-controlled RCT (n= 43,783) which found the vaccine was 67% and 66% effective in preventing moderate to severe/critical COVID-19 occurring at 14 days and 28 days after vaccination, respectively.

Source:

US Food and Drug Administration